Kaskela Law Investigates FONAR Buyout for Potential Undervaluation
Event summary
- Kaskela Law is investigating FONAR Corp.'s proposed $19.00 per share buyout announced on December 29, 2025.
- The investigation focuses on whether the buyout price undervalues FONAR's shares and if company officers breached fiduciary duties.
- FONAR shareholders will be cashed out, and the company's shares will no longer be publicly traded post-transaction.
- Kaskela Law encourages FONAR stockholders to contact them for information on legal rights and options.
The big picture
Kaskela Law's investigation into FONAR's buyout highlights the growing scrutiny over fair valuation in private equity acquisitions. This case could set a precedent for how similar transactions are evaluated, particularly in the medical technology sector where valuation metrics can be highly specialized. The outcome may influence future M&A activity and corporate governance practices in the industry.
What we're watching
- Valuation Dispute
- Whether the $19.00 per share buyout price will be challenged as undervaluing FONAR's true market value.
- Legal Scrutiny
- The potential legal ramifications for FONAR's officers and directors if fiduciary duties are found to have been breached.
- Market Reaction
- How the investigation and potential legal actions may impact investor confidence and FONAR's remaining public trading period.
Related topics